NASDAQ:YTEN Yield10 Bioscience (YTEN) Stock Price, News & Analysis → 4x Better than Bitcoin (From Behind the Markets) (Ad) Free YTEN Stock Alerts $0.38 0.00 (0.00%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$0.35▼$0.4550-Day Range$0.19▼$0.4352-Week Range$0.18▼$3.29Volume2.68 million shsAverage Volume6.51 million shsMarket Capitalization$4.55 millionP/E RatioN/ADividend YieldN/APrice Target$3.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Yield10 Bioscience alerts: Email Address Yield10 Bioscience MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside821.1% Upside$3.50 Price TargetShort InterestHealthy2.00% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.67Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.16 out of 5 stars 3.2 Analyst's Opinion Consensus RatingYield10 Bioscience has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.50, Yield10 Bioscience has a forecasted upside of 821.1% from its current price of $0.38.Amount of Analyst CoverageYield10 Bioscience has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.00% of the outstanding shares of Yield10 Bioscience have been sold short.Short Interest Ratio / Days to CoverYield10 Bioscience has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Yield10 Bioscience has recently decreased by 17.42%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldYield10 Bioscience does not currently pay a dividend.Dividend GrowthYield10 Bioscience does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for YTEN. Previous Next 2.6 News and Social Media Coverage News SentimentYield10 Bioscience has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Consumer Staples companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Yield10 Bioscience this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for YTEN on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat Follows4 people have added Yield10 Bioscience to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Yield10 Bioscience insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.30% of the stock of Yield10 Bioscience is held by insiders.Percentage Held by InstitutionsOnly 4.91% of the stock of Yield10 Bioscience is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Yield10 Bioscience is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Yield10 Bioscience is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioYield10 Bioscience has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets4x Better than Bitcoin4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Yield10 Bioscience Stock (NASDAQ:YTEN)Yield10 Bioscience, Inc. operates as agricultural bioscience company in the United States. The company primarily focus on production of low carbon products through processing Camelina seeds. Its products include Camelina oil for low carbon biofuel feedstock; Omega-3 oils for nutrition; and PHA bioplastics for biodegradable zero waste packaging solutions. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was incorporated in 1992 and is headquartered in Woburn, Massachusetts.Read More YTEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart YTEN Stock News HeadlinesMarch 28, 2024 | globenewswire.comYield10 Bioscience to Announce Fourth Quarter and Full Year 2023 Financial Results and Host a Conference Call on Monday, April 1, 2024March 26, 2024 | globenewswire.comYield10 Bioscience Announces that the Plant Biosafety Office of the Canadian Food Inspection Agency has Cleared Genome-edited E3902 Camelina for Planting in CanadaMarch 29, 2024 | Behind the Markets (Ad)4x Better than Bitcoin4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 23, 2024 | stockhouse.comUSDA-APHIS Determines that Yield10 Bioscience's Omega-3 Camelina Varieties May Be Planted and Bred in the United StatesMarch 23, 2024 | americanbankingnews.comYield10 Bioscience (NASDAQ:YTEN) Stock Price Passes Above 200 Day Moving Average of $0.28March 21, 2024 | markets.businessinsider.comDow Jumps 200 Points; US Weekly Jobless Claims FallMarch 21, 2024 | markets.businessinsider.comUSDA-APHIS Determines that Yield10 Bioscience’s Omega-3 Camelina Varieties May Be Planted and Bred in the United StatesMarch 21, 2024 | msn.comYield10 stock soars 120% on USDA okay for Camelina plantingMarch 29, 2024 | Behind the Markets (Ad)4x Better than Bitcoin4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 21, 2024 | finance.yahoo.comUSDA-APHIS Determines that Yield10 Bioscience’s Omega-3 Camelina Varieties May Be Planted and Bred in the United StatesMarch 21, 2024 | investorplace.comWhy Is Yield10 (YTEN) Stock Up 117% Today?March 21, 2024 | globenewswire.comUSDA-APHIS Determines that Yield10 Bioscience's Omega-3 Camelina Varieties May Be Planted and Bred in the United StatesMarch 10, 2024 | barrons.comYield10 Bioscience Inc.February 29, 2024 | globenewswire.comYield10 Bioscience Reports that Proprietary Varieties of Winter Camelina Show Tolerance to Commonly Used Herbicides in First Field TestsFebruary 14, 2024 | finance.yahoo.comYield10 Bioscience Grants Global License to VISION Bioenergy Oilseeds for Herbicide Tolerant Camelina Cultivated for the Production of Biofuel FeedstockFebruary 14, 2024 | globenewswire.comYield10 Bioscience Grants Global License to VISION Bioenergy Oilseeds for Herbicide Tolerant Camelina Cultivated for the Production of Biofuel FeedstockFebruary 9, 2024 | msn.comYield10 Bioscience Accelerates Omega-3 Camelina LaunchFebruary 9, 2024 | finanznachrichten.deYield10 Bioscience, Inc.: Yield10 Bioscience Provides an Update on its Omega-3 Camelina ProgramFebruary 8, 2024 | realmoney.thestreet.comYield10 Bioscience just downgraded at Lake Street, here's whyFebruary 8, 2024 | msn.comWhat's Going On With Yield10 Bioscience (YTEN) Stock?February 7, 2024 | finance.yahoo.comYield10 Bioscience Provides an Update on its Omega-3 Camelina ProgramFebruary 5, 2024 | msn.comDow Tumbles 150 Points; McDonald's Sales Miss ViewsFebruary 5, 2024 | investorplace.comWhy Is Yield10 Bioscience (YTEN) Stock Up 34% Today?January 8, 2024 | finance.yahoo.comYield10 Bioscience Files Request for Regulatory Status Review with USDA-APHIS for Camelina Designed to Produce the EPA and DHA Components of Omega-3 OilDecember 12, 2023 | morningstar.comYield10 Bioscience Inc YTENNovember 17, 2023 | msn.comMaxim Group Downgrades Yield10 Bioscience (YTEN)November 16, 2023 | markets.businessinsider.comRegulatory Milestones and Commercialization Progress Drive Buy Rating for Yield10 Bioscience: An Analyst’s PerspectiveSee More Headlines Receive YTEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Yield10 Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today3/29/2024Next Earnings (Estimated)4/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorConsumer Staples Industry Agricultural production - crops Sub-IndustryN/A Current SymbolNASDAQ:YTEN CUSIPN/A CIK1121702 Webwww.yield10bio.com Phone(617) 583-1700Fax617-583-1768Employees30Year Founded1992Price Target and Rating Average Stock Price Target$3.50 High Stock Price Target$4.00 Low Stock Price Target$3.00 Potential Upside/Downside+821.1%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,570,000.00 Net MarginsN/A Pretax Margin-9,770.75% Return on Equity-888.81% Return on Assets-228.84% Debt Debt-to-Equity RatioN/A Current Ratio0.85 Quick Ratio0.85 Sales & Book Value Annual Sales$450,000.00 Price / Sales10.12 Cash FlowN/A Price / Cash FlowN/A Book Value$0.89 per share Price / Book0.43Miscellaneous Outstanding Shares11,980,000Free Float11,346,000Market Cap$4.55 million OptionableNot Optionable Beta1.51 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Oliver P. Peoples Ph.D. (Age 66)Co-Founder, President, CEO & Director Comp: $344.48kDr. Anthony J. Sinskey Ph.D. (Age 84)Sc.D., Co-Founder & Independent Director Comp: $62.5kDr. Kristi D. Snell (Age 56)VP of Research & Chief Science Officer Comp: $278.69kMs. Lynne H. Brum (Age 60)VP of Planning & Corporate Communications and Secretary Comp: $278.69kMr. Charles B. Haaser (Age 68)VP of Finance, Chief Accounting Officer & Treasurer Comp: $236.41kDr. Nicholas Renegar Ph.D.Director of Business Analytics & OperationsMore ExecutivesKey CompetitorsAfrican AgricultureNASDAQ:AAGREdible GardenNASDAQ:EDBL22nd Century GroupNASDAQ:XXIIFarmmiNASDAQ:FAMIStryve FoodsNASDAQ:SNAXView All CompetitorsInsidersJack W SchulerSold 36,000 sharesTotal: $7,560.00 ($0.21/share)Jack W SchulerSold 35,000 sharesTotal: $8,400.00 ($0.24/share)Jack W SchulerSold 37,931 sharesTotal: $11,379.30 ($0.30/share)Jack W SchulerSold 41,399 sharesTotal: $12,833.69 ($0.31/share)Jack W SchulerBought 765,000 shares on 8/15/2023Total: $497,250.00 ($0.65/share)View All Insider Transactions YTEN Stock Analysis - Frequently Asked Questions Should I buy or sell Yield10 Bioscience stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Yield10 Bioscience in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" YTEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in YTEN, but not buy additional shares or sell existing shares. View YTEN analyst ratings or view top-rated stocks. What is Yield10 Bioscience's stock price target for 2024? 3 Wall Street research analysts have issued 12-month price targets for Yield10 Bioscience's shares. Their YTEN share price targets range from $3.00 to $4.00. On average, they expect the company's share price to reach $3.50 in the next twelve months. This suggests a possible upside of 821.1% from the stock's current price. View analysts price targets for YTEN or view top-rated stocks among Wall Street analysts. How have YTEN shares performed in 2024? Yield10 Bioscience's stock was trading at $0.2393 at the beginning of the year. Since then, YTEN stock has increased by 58.8% and is now trading at $0.38. View the best growth stocks for 2024 here. When is Yield10 Bioscience's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 2nd 2024. View our YTEN earnings forecast. How were Yield10 Bioscience's earnings last quarter? Yield10 Bioscience, Inc. (NASDAQ:YTEN) issued its earnings results on Tuesday, November, 9th. The specialty chemicals company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.16. The specialty chemicals company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.22 million. During the same quarter in the prior year, the business earned ($0.87) EPS. When did Yield10 Bioscience's stock split? Yield10 Bioscience shares reverse split on Thursday, January 16th 2020. The 1-40 reverse split was announced on Wednesday, January 15th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 15th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Yield10 Bioscience own? Based on aggregate information from My MarketBeat watchlists, some companies that other Yield10 Bioscience investors own include KushCo (KSHB), OPKO Health (OPK), T2 Biosystems (TTOO), FuelCell Energy (FCEL), TherapeuticsMD (TXMD), Viking Therapeutics (VKTX), Rigel Pharmaceuticals (RIGL), Advanced Micro Devices (AMD). How do I buy shares of Yield10 Bioscience? Shares of YTEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:YTEN) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & CompanyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Yield10 Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.